Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$49.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Kamada Ltd announces significantly improved infusion rate for Glassia


Thursday, 24 Apr 2014 08:00am EDT 

Kamada Ltd:Significantly improved infusion rate for Glassia (Alpha1-Proteinase Inhibitor -Human).Says this improvement was recently approved by the U.S. Food and Drug Administration (FDA).Glassia, which is marketed in U.S. through strategic partnership by Baxter International Inc., is first and only ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) approved by FDA.Says also indicated as chronic augmentation and maintenance therapy in adults with alpha-1 antitrypsin deficiency (AATD, or Inherited Emphysema).Improved infusion rate is highly important because it reduces the overall time from preparation to finish, which is key for AATD patients who are using this therapy chronically and for life.For the average patient weighing ~70kg, the new infusion rate reduces the weekly infusion time from 70 minutes to 15 minutes.This along with its ready-to-use feature makes Glassia a highly user friendly and convenient product that supports patient quality of life. 

Company Quote

1836.0
-27.0 -1.45%
6:14am EDT